mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours

Authors


Wulbrand Zentrum für medizinische Forschung, Abteilung für Transfusionsmedizin, Eberhard-Karls-Universität Tübingen, Waldhörnlestraße 22, 72072 Tübingen, Germany. Tel.: 0049–7071–29–81109; fax: 0049–7071–29–5142; e-mail: ulrich.wulbrand@uni-tuebingen.de

Abstract

Background

Insulin-like growth factors (IGF) and their corresponding receptors and binding proteins are important in carcinogenesis for several tumours, but their expression pattern in the functionally and biologically heterogeneous human neuroendocrine tumours of the gastroenteropancreatic tract is largely unknown.

Materials and methods

This study searched for the mRNA expression patterns of components of the IGF system: IGF-1 and IGF-2, IGF receptors 1 and 2 (IGF-1R, IGF-2R), IGF-binding proteins 1–6 (IGFBP1–6)) in the most frequent human gastroenteropancreatic neuroendocrine tumours (gastrinomas, insulinomas, tumours associated with carcinoid syndrome and functionally inactive tumours) employing reverse transcriptase-polymerase chain reaction (RT-PCR).

Results

In the 37 tumour samples analysed (nine gastrinomas, 10 insulinomas, nine tumours associated with carcinoid syndrome and nine functionally inactive tumours) IGFBP-2 was found in all tumour samples while the IGFBP-1 was expressed only at low frequency (10–22%) among the four tumour types. The IGF-2R was predominantly expressed in gastrinomas. Among the four tumour types the expression of IGF-1R, IGF-2R and IGFBP-6 varied significantly. In addition, 12 pairs of significantly coexpressed IGF system components were detected (IGF-1 ↔ IGF-1R, IGF-1 ↔ IGF-2R, IGF-1 ↔ IGFBP-3, IGF-1 ↔ IGFBP-6, IGFBP-3 ↔ IGF-1R, IGFBP-6 ↔ IGF-1R, IGFBP-1 ↔ IGF-2R, IGFBP-3 ↔ IGF-2R, IGFBP-5 ↔ IGF-2R, IGFBP-3 ↔ IGFBP-5, IGFBP-3 ↔ IGFBP-6, IGFBP-5 ↔ IGFBP-6).

Conclusions

The described differences of the expression patterns of the IGF system components in neuroendocrine tumour subtypes suggest tumour type-dependent different pathways in tumour growth control by IGF system components.

Ancillary